ArticleBlood cancer journal2025

A phase 2 study of Daratumumab with Thalidomide and dexamethasone in relapsed and/or Refractory Myeloma (RRMM).

Chandramouli Nagarajan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.